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How cancer cells acquire the competence to colonize distant organs remains a central question in cancer
biology. Tumors can release large numbers of cancer cells into the circulation, but only a small proportion
of these cells survive on infiltrating distant organs and even fewer form clinically meaningful metastases.
During the past decade, many predictive gene signatures and specific mediators of metastasis have been
identified, yet how cancer cells acquire these traits has remained obscure. Recent experimental work and
high-resolution sequencing of human tissues have started to reveal the molecular and tumor evolutionary
principles that underlie the emergence of metastatic traits.The molecular and tumor evolutionary basis of metastasis is a
long-standing problem that particularly in the past few years
has started to move toward a resolution. Important elements of
the biologically complex metastatic cascade (Talmadge and
Fidler, 2010; Valastyan and Weinberg, 2011), its dynamic and
kinetic diversity across different cancer types and patient popu-
lations (Chiang and Massague´, 2008), and the strong stochastic
nature at the cellular level (Kienast et al., 2010; Luzzi et al., 1998)
are coming to light at a brisk tempo. Work during the past
decade has demonstrated that the problem of metastasis can
be tackled experimentally at the molecular level. Progress in
experimental models and clinical research have led to the iden-
tification of genes that mediate various steps of the metastatic
cascade in different tumor types and target organs (Ell and
Kang, 2012; Guise, 2009; Nguyen et al., 2009a; Talmadge and
Fidler, 2010; Valastyan and Weinberg, 2011). Increased genome
sequencing output has facilitated the analysis of clonal relation-
ships between primary tumors and secondary lesions in clinical
samples (Campbell et al., 2010; Gerlinger et al., 2012; Yachida
et al., 2010). Taken together, these developments have revealed
a set of principles that illuminate fundamental questions on the
origins of metastatic traits. We resort to specific examples in or-
der to review here the nature and implications of these advances.
Early Ideas
The classical view of tumor progression, based on the clonal
evolutionary theory of cancer (Nowell, 1976), postulated that
the metastatic ability is conferred by random mutations in pri-
mary tumor cells that remain rare until clonally expanded and
selected at secondary organ sites (Fidler and Kripke, 1977).
This Darwinian view for metastatic progression was intuitively
appealing and supported by evidence from cancer cell trans-
plantation experiments in mice (Fidler and Kripke, 1977; Kripke
et al., 1978). Clinical observations were also consistent with
the view that metastasis is a rare achievement for cells in a
primary tumor, although one that follows predictable patterns
suggestive of specific mutations being responsible for its devel-
opment (Hess et al., 2006). Identifying these driver mutations,
however, remained an elusive goal.
Indications that the clonal selection model alone was not suf-
ficient to explain the development of metastatic traits emerged410 Cancer Cell 24, October 14, 2013 ª2013 Elsevier Inc.with the advent of genome-wide transcriptomic techniques
and their application to tumor samples. It became evident that
the likelihood of metastasis in many types of cancer could be
predicted from the overall gene expression profile of primary
tumors (van ’t Veer et al., 2002; van de Vijver et al., 2002), sug-
gesting that large segments of the cancer cell population con-
tained traits that predisposed these tumors to metastasis. This
was hard to reconcile with the idea of rare mutations as the
main cause of metastatic progression. It was proposed that
metastases may instead be an outcome of the same oncogenic
forces that drive the emergence of primary tumors (Bernards and
Weinberg, 2002). Experimental evidence for primary oncogenic
mutations as drivers of metastasis had precedent (Staller et al.,
2003). This view, however, had its problems too, as cancer so
clearly was an evolutionary phenomenon (Greaves and Maley,
2012). It was hard to imagine how metastasis could not be the
end result of strong selection imposed by different microenviron-
ments. A complementary view invoked the ‘‘seed-and-soil’’
hypothesis that was first enunciated by Paget in the 19th century
and, in today’s language, stated that cancer cells may seed
metastasis so long as they reach a compatible tissue microenvi-
ronment (Fidler, 2003). Compelling evidence has since accumu-
lated that partially supports each of these early ideas.
Metastasis Steps
The formation of clinically detectable metastasis is the end result
of a series of stochastic events that first allow cancer cells to
disperse and survive in distant sites and later to grow as second-
ary tumors (Figure 1). This process comprises steps of cancer
cell migration, local invasion, entry into the circulation, arrest at
secondary sites, extravasation, and colonization. The use of
‘‘colonization’’ as a single term belies the highly complex and
demanding process that awaits infiltrated cancer cells in distant
organs. Colonization can be parsed into steps of cancer cell sur-
vival upon entry into the tissue, formation of micrometastasis,
adoption of latency states that can last up to decades, reactiva-
tion of growth in the latent micrometastases, aggressive over-
taking of the host tissue, recirculation, and formation of tertiary
lesions in the same or different organs (Figure 1).
Viewing these steps as orderly cell biological phenomena akin
to developmental programs has been useful for mechanistic
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Figure 1. Metastasis Steps and Bottlenecks
The sequence of metastasis steps starts with the
dissemination of cancer cells from the primary
tumor and ends in the formation of clinically
detectable macrometastases. Whereas dissemi-
nation is not severely rate limiting, only a small
fraction of disseminated cells form micrometa-
stases, and only a small minority of micrometa-
stases become macrometastases. A cancer cell
may reach distant organ capillaries within seconds
of departing from a primary tumor and extravasate
into the parenchyma within hours, but it may
remain latent for decades. Progression of metas-
tasis through each of these bottlenecks requires
several specialized functions including cancer cell-
autonomous functions and the cooption of various
components of the target tissue stroma. The prin-
cipal functions involved in each step are listed in
each box. The thickness of the arrows reflects the
relative rate of success of cancer cells at each
transition. Residual tumor cells remaining after
treatment (Rx) may rely on functions that had been
previously selected during the micrometastatic
state. Individual metastatic traits, e.g., the ex-
pression of a metastasis gene, mediate particular
functions that slightly increase the probability
that a cancer cell will perform a particular step of
metastasis. All metastatic traits combined deter-
mine the probability that cancer cells will achieve
overt metastasis. For an individual cancer cell
this probability is very small, but for a large cancer
cell population this probability can be absolute.
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fication of a number of metastasis promoting and suppressing
genes and functions (Valastyan and Weinberg, 2011). However,
cancer is not a developmental program but an evolutionary pro-
cess during which only a minority of malignant cells succeed. In
this process, themediators of metastasis function as factors that
slightly increase, on a per cell basis, the probability of successful
completion of one or more steps of the metastatic cascade.
Metastasis Bottlenecks
Biologically, metastasis is a highly inefficient process. Aggres-
sive tumors are thought to release cancer cells into the circula-
tion by the thousands each day, as can be inferred from the
numbers of circulating tumor cells (CTCs) present in the blood
of cancer patients (Baccelli et al., 2013; Nagrath et al., 2007;
Stott et al., 2010) and experimental models systems (Yu et al.,
2012). Much research has revealed in exquisite detail the molec-
ular underpinnings of cell invasion, motility, and stromal interac-
tions that lead cancer cells to enter the circulation and reach
distant organs (Kessenbrock et al., 2010; Roussos et al., 2011).
However, leaving a tumor is the easy part. The odds that an
aggressive cancer cell in the circulation will form a metastatic
colony in some organ are vanishingly small.
Most cancer cells that leave a tumor die, andmuch of this attri-
tion happens as the circulating cancer cells infiltrate distant
organs (Kienast et al., 2010; Luzzi et al., 1998). Even cell popula-
tions that are experimentally enriched for metastasis-initiating
cells suffer extreme attrition in the organs that they invade
(Chambers et al., 2002). For example, cancer stem cells isolated
from patients with metastatic melanoma are capable of forming
a tumor when individually implanted in the skin of a mouse (Quin-
tana et al., 2008), but would probably not form a metastasis if
individually inoculated in the general circulation. The same istrue for colorectal cancer (CRC) cells when challenged to colo-
nize the liver parenchyma (Calon et al., 2012).
The main bottlenecks for metastasis formation therefore seem
to occur during the colonization of distant organs (Figure 1). The
metastatic compatibility of certain tissues as envisioned by the
seed-and-soil hypothesis is only relative. To infiltrating cancer
cells, the best soil is still a deadly soil, just a bit less deadly
than others. The stress of passing through endothelial barriers,
a lack of survival signals and a supportive stroma in the host tis-
sue, and an overexposure of solitary cancer cells to the perils of
innate immunity challenge cancer cells that infiltrate distant or-
gans (Chambers et al., 2002; Nguyen et al., 2009a; Vesely
et al., 2011). Why cancer cells so easily die at distant sites is
currently unknown, but this death en masse represents a major
barrier to metastatic cancer progression. Clinically, it is also
the most relevant barrier, because previous steps of cancer
cell emigration from primary tumors and distribution to distant
organs have already occurred for months at the time of cancer
diagnosis. Identifying the natural mechanisms that eliminate
disseminated cancer cells might facilitate the development of
new therapeutic strategies to prevent or combat metastasis.
Metastatic Latency
Overt metastasis may eventually arise from residual populations
of disseminated cancer cells that managed to survive in host
tissues. Clinically, ‘‘metastatic latency’’ refers to the period
elapsed between the diagnosis of a primary tumor and the emer-
gence of detectable metastatic lesions. At the cell biological
level, latency also refers to various states that disseminated
cancer cells may adopt during this period of indolence. These
states include growth arrest (‘‘dormancy’’) of solitary or micro-
metastatic cancer cells and unproductive micrometastatic
growth with cell proliferation counterbalanced by cell death orCancer Cell 24, October 14, 2013 ª2013 Elsevier Inc. 411
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Figure 2. Determinants of Metastatic Organ
Tropism
(A) Metastasis as a whole, and organ tropism in
particular, are determined by traits that operate in
two consecutive, but temporally separate stages:
establishment of a disseminated tumor cell pop-
ulation and development of overt metastasis.
Depending on the tumor type, the separation
between these two stages as determined by their
clinical manifestation may be weeks (e.g., in lung
adenocarcinoma) or decades (e.g., in ER-positive
breast cancer). The organ tropism of cancer cell
dissemination and micrometastasis is determined
by circulation patterns from the primary tumor to
different distant organs, the permissiveness of
capillary walls to extravasation, and the presence
of locations (‘‘niches’’) in the invaded parenchyma
that provide a supporting home for the survival and
stemness of disseminated tumor cells. Capillary
walls can be permissive for extravasation (e.g., in
the fenestrated capillaries of the bone marrow),
difficult (e.g., in the capillaries of the lungs) or very
difficult (e.g., the brain-blood barrier capillaries).
The organ tropism of the overt colonization is
determined by the existence of signals that re-
activate latent metastatic cells, the ability of these
cells to co-opt specialized components of the parenchyma (e.g., osteoclasts in the bonemarrow, astrocytes in the brain), and the ability to evade therapy owing to
drug access or intrinsic drug resistance properties.
(B) Each type of cancer has a typical pattern of metastatic relapse, initially involving mainly one organ (e.g., prostate cancer metastasis to bone, sarcoma
metastasis to lung) or multiple organs (e.g., lung and breast carcinomas). Therapeutic treatments may suppress metastasis in all organs uniformly (as in
‘‘Cancer A’’) or in some organs more than in others (as in ‘‘Cancer B’’). In the latter case, clinical management of the cancer alters the organ metastatic pattern of
the disease.
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coexist in the population of disseminated cancer cells residing in
a patient. The biology of metastatic latency and reactivation is
largely unknown, at least partially due to the lack of suitable
experimental systems that would model this aspect of metas-
tasis. However, recent work in mouse models of breast cancer
provides insights into the kind of differentiation signals and stro-
mal interactions that may be involved (Gao et al., 2012; Lu et al.,
2011).
The clinical course of metastatic tumor progression can vary
dramatically between tumor types and between patients.
Some locally invasive cancers, such as glioblastomas, form
distant metastases only rarely (Beauchesne, 2012; Lun et al.,
2011), whereas other tumors of the brain, such as medulloblas-
toma, frequently metastasize (Wu et al., 2012). Lung and pancre-
atic cancers are frequently associated with metastasis at the
time of diagnosis (Feld et al., 1984; Werner et al., 2013) whereas
breast and prostate cancers are not (Lim et al., 2012; Popiolek
et al., 2013). Some tumors metastasize so avidly that cancer in
these patients is diagnosed as metastases of unknown primary
source (Pavlidis and Pentheroudakis, 2012).
Assessing the true temporal patterns of primary tumor, latent
metastasis, and overt metastasis only based on clinical observa-
tion is challenging. For example, pancreatic adenocarcinoma
was thought to metastasize early because in many cases metas-
tasis is already present at the time of disease diagnosis. How-
ever, mathematical modeling of exome sequencing data from
matched primary and metastatic lesions suggests that this
may be due to late diagnosis, not early metastasis, and the
development of metastatic pancreatic cancer may in fact take
decades (Yachida et al., 2010). Nevertheless, the fact that
some tumor types, such as estrogen-positive breast cancer
(Lim et al., 2012) and prostate cancer (Popiolek et al., 2013),412 Cancer Cell 24, October 14, 2013 ª2013 Elsevier Inc.are associated with long latency periods between primary tumor
resection and the development of metastasis indicates that
cancer cells in these tumors are disseminated long before they
acquire the capabilities of metastatic colonization.
Metastasis Organ Tropism
Solid tumors display dramatic variation in the pattern of metas-
tasis. Some mainly relapse in one particular organ (e.g., prostate
cancers in bone, ocular melanomas in liver, sarcomas in lungs)
whereas others relapse in multiple organs (e.g., triple-negative
breast cancers, skin melanomas, lung cancers, renal carci-
nomas). Blood circulation patterns can direct cancer cells to a
particular organ, as in the case of the mesenteric circulation di-
recting CRC cells to the liver. However, most solid tumors
release cells into the general circulation reaching many organs.
The fenestrated endothelium of bonemarrow and liver capillaries
is more permissive than are the contiguous capillary walls in
other organs, particularly in the brain. The capacity of circulating
cancer cells to pass through endothelial walls may, therefore, in-
fluence the organ tropism of tumors. Furthermore, because the
vast majority of cancer cells infiltrating a distant organ die, the
capacity of circulating cancer cells to resist decimation in spe-
cific organ microenvironments is another determinant of organ-
specific metastasis (Nguyen et al., 2009a) (Figure 2A).
Mediators of extravasation have been identified (Bos et al.,
2009; Clark et al., 2000; Gupta et al., 2007; Padua et al., 2008;
Weis et al., 2004; Wolf et al., 2012). Expression of these genes
in cancer cells increases their accumulation as disseminated
seeds in susceptible organs, thereby augmenting the probability
of eventual relapse in those organs. The same applies to media-
tors of cancer cell survival in distant organs (Chen et al., 2011;
Valastyan et al., 2009; Zhang et al., 2009). The expression of
these mediators in broad segments of the cancer cell population
Cancer Cell
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predict relapse to various organs in clinical tumor cohorts
(Bos et al., 2009; Cheung et al., 2013; Minn et al., 2005; Nguyen
et al., 2009b; Padua et al., 2008; Tavazoie et al., 2008; Valastyan
et al., 2009; Vanharanta et al., 2013; Zhang et al., 2009). These
findings have provided important insights into the biology ofmet-
astatic dissemination and the proteins and microRNAs medi-
ating it.
Although circulation patterns, extravasation barriers, and sur-
vival on arrival are three key determinants of the capacity of
particular tumors to seed specific organs, a different set of con-
ditions determine the capacity of micrometastatic seeds to
develop into macrometastases (Figure 2A). Overt colonization
critically depends on the capacity of disseminated cancer cells
to benefit from specific stromal components in a particular
organ. For example, cancer cells exploit osteoclasts in the
bone marrow for osteolytic metastasis (Ell and Kang, 2012;
Guise, 2009) and astrocytes in the brain parenchyma for cerebral
metastasis (Kim et al., 2011; Xing et al., 2013). These traits may
come into play only when disseminated cells emerge from the
latent state, months to decades after having seeded that organ.
This implies that in addition to the tumor reinitiation phenotypes
inherited from the cell-of-origin or acquired during earlier steps
of tumor progression, some of the overt colonization traits may
be selected only after micrometastatic cells initiate aggressive
outgrowth in the target organ parenchyma.
Both the determinants of metastatic seeding as well as those
of overt colonization of different organs underlie the patterns of
metastatic organ tropism of each type of cancer (Figure 2A),
that is, the probability that a particular cancer will relapse in
specific organ sites. It is possible that in the absence of an
effective treatment, and if given enough time, metastasis would
emerge in all organs in every case. Indeed, advances in disease
management are prolonging the life of patients with metastases,
but also changing the patterns of metastasis in certain types of
cancer (Figure 2B). For example, a current rise in the incidence
of brain metastasis of HER2+ breast cancer is attributable to
the fact that therapeutic agents targeting the HER2 oncoprotein
are effective in controlling extracranial metastases but less
effective against brain metastases (Sledge, 2010). Thus, differ-
ences in sensitivity to therapy of disseminated cancer cells in
different organs constitute one more determinant of metastasis
patterns.
Clonal Evolution and Tumor Heterogeneity
Genetic Analysis of Human Cancer
Cancers arise through cycles of mutation and clonal selection
(Stratton et al., 2009). A classical genetic model of human cancer
progression is provided by the analysis of CRC development.
These tumors arise through progression of small adenomas
into full-blown carcinoma with associated mutations that drive
tumor progression (Fearon and Vogelstein, 1990). Inactivation
of the APC tumor suppressor is the gatekeeper event, followed
by mutations in KRAS, TP53, SMAD4, PIK3CA, TGFBR2, and
others (Jones et al., 2008). Based on these observations, it
was envisioned that yet other genetic alterations would make
carcinomas metastatic (Fearon and Vogelstein, 1990). When
technology enabled exome sequencing of human tumor sam-
ples, a comparison of primary tumors and matched metastasesfound no mutations in CRC that were specifically and recurrently
associated with metastasis (Jones et al., 2008).
Two important conclusions emerged from these studies. First,
the intervening period between tumor initiation, i.e., the time
when normal cells turn into premalignant precursors of cancer,
and the emergence of invasive carcinoma far exceeds the addi-
tional time that it takes for the development of metastasis (Jones
et al., 2008). Second, mathematical modeling of tumor evolution
based on the genetic data suggested that the selective advan-
tage provided by individual driver mutations is on average rather
low, only 0.4% (Bozic et al., 2010).
These lessons are complemented with insights from other
cancers. Instead of recurrent metastasis-specific mutations,
alterations are found in genes that are commonly mutated in
primary tumors. For example, comparative genomic sequencing
of several tumor specimens of the same patient has revealed
metastasis-associated mutations in renal, pancreatic, and
lobular breast cancers (Gerlinger et al., 2012; Shah et al., 2009;
Yachida et al., 2010). Metastatic clones in pancreatic cancer
may harbor amplifications of the oncogenes KRASG12V, MYC,
and CCNE1 (Campbell et al., 2010). Mutant alleles of the tumor
suppressors TP53, SETD2, and KDM5C were found in renal car-
cinoma metastases (Gerlinger et al., 2012). In a patient with ER-
positive breast cancer from whommetastatic cells were isolated
9 years after primary tumor resection, the most compelling
metastasis driver mutation was in ERBB2 (Shah et al., 2009),
which harbors similar activating mutations in primary breast can-
cers as well (Bose et al., 2013; Cancer Genome Atlas Network,
2012). In basal breast cancer, a similar approach revealed differ-
ences in mutant allele frequencies between primary and meta-
static tumors, but the affected genes were the same with few
exceptions (Ding et al., 2010). Single cell analysis of a triple nega-
tive breast cancer resulted in compatible observations (Navin
et al., 2011).
Although no metastasis-specific, recurrent, driver mutations
have been demonstrated thus far, metastatic cell clones clearly
do not represent the whole primary tumor population, but only
parts of it (Campbell et al., 2010; Gerlinger et al., 2012; Yachida
et al., 2010). In a pancreatic cancer, lung metastases and perito-
neal metastasis were shown to descend from different clones in
the primary tumor (Campbell et al., 2010; Yachida et al., 2010),
demonstrating in tissue samples what has long been clear in
experimental models of metastasis: different metastatic clones
differ in their ability to colonize specific organs (Nguyen et al.,
2009a). In prostate cancer, on the other hand, metastatic tumors
in different target organs seem to arise from a single metastatic
clone (Liu et al., 2009).
The longer the latency period between the emergence of a pri-
mary tumor and that of distant metastases, the more likely it is
that metastatic clones will carry specific genetic alterations.
The pressure to adapt to, alter, and eventually overtake the
host stroma combined with the genetic drift of genomically un-
stable cancer cells all but ensure that some genetic alterations
will be enriched for in metastatic clones. The number of metasta-
tic tumor specimens that have been analyzed in comparative
genomic studies remains low, and it is not clear whether any of
the metastasis-associated driver mutations identified have
higher mutation frequencies in metastatic lesions more generally
(Figure 3). An emerging conclusion suggests, however, that theCancer Cell 24, October 14, 2013 ª2013 Elsevier Inc. 413
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Figure 3. Genetic Alterations in Metastatic Cancer
A schematic shows the possible classes of metastasis-associated cancer
driver mutations as a continuum ranging from primary tumor-specific to
metastasis-specific genetic lesions. Systematic cancer genome resequencing
efforts are beginning to shed light on the mutational complement of metastatic
cancers by comparing the genetic alterations in primary tumors and corre-
sponding metastatic lesions in a procedure termed comparative lesion
sequencing (Jones et al., 2008). Ideally, several regions of individual tumors
are sampled in order to account for clonal heterogeneity. Mutations that would
have a higher selective advantage at the metastatic site would also have a
higher mutation frequency in metastatic lesions. Conversely, some mutations
that are advantageous at the primary site might make cancer cells less fit for
metastatic progression, in which case the mutation frequency would be higher
in primary tumors. At extremes, a type of mutation would be either fully
metastasis- or primary tumor-specific, respectively. Relative difference in
mutational frequency between primary andmetastatic cancer (Df) is defined as
[f(T)  f(M)]/[f(T) + f(M)], where f(T) and f(M) refer to the mutational frequency of
a gene in primary tumors and corresponding metastasis, respectively. a,
Mutations with higher frequency in primary tumor; b, mutations with equal
frequency in both primary and metastatic tumors; g, mutations with higher
frequency in metastatic tumors; d, metastasis-specific mutations.
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ucts is not likely to be metastasis-specific.
Lessons from Mouse Models
Recent work combining analysis of human tissues and mouse
models of CRC revealed a strong impact of nongenetic events
on the probability of liver metastasis (Calon et al., 2012). CRC
cells that frequently become insensitive to the tumor suppressive
action of TGF-b via genetic inactivation of the TGF-b signaling
pathway can afford to overexpress this cytokine, which
enhances metastasis-formation in the liver by inducing the
secretion of the prosurvival cytokine interleukin-11 from stromal
fibroblasts (Calon et al., 2012). Thus, a genetic event in cancer
cells enables the selection of a trait—high expression of TGF-
b—that strongly favors metastasis by profitably engaging the
stroma. What drives the high expression of TGF-b in TGFBR2
mutant CRC cells may not be another mutation but rather a
diverse set of epigenomic regulators of TGF-b production, any
of which underlies this highly valuable trait.
Several studies have identified pathways that promote or
suppress metastasis in genetically engineered mouse models
of cancer. Tumor initiation byPten loss in the prostate can trigger
activation of the TGF-b tumor-suppressor pathway through
SMAD4 expression (Ding et al., 2011). In this context, yet uniden-
tified signals can induce the expression of COUP-TF2, which can
inhibit SMAD4 and consequently allow the tumors to metasta-
size to lymph nodes and the lungs (Qin et al., 2013). Sim-
ultaneous inactivation of Pten, Tp53, and Smad4 in the mouse
prostate gives rise to aggressive tumors with some bone meta-
static activity, whereas tumors with Pten and Tp53 mutations414 Cancer Cell 24, October 14, 2013 ª2013 Elsevier Inc.alone are more indolent (Ding et al., 2012b). Smad4 inactivation
thus seems to be a critical event in the development of advanced
prostate cancer that eventually may also form metastasis. Simi-
larly, Nkx2.1 loss in KrasG12D/Tp53/-driven lung adenocarci-
nomas allows tumor progression and metastasis (Winslow
et al., 2011). Activation of Notch signaling upon Aes deletion in
mouse intestinal tumors promotes local invasion, extravasation,
and metastasis (Sonoshita et al., 2011). These mouse studies
point at important pathways as mediators of tumor progression,
including metastasis, but they do not provide evidence for
metastasis-restricted genetic alterations. A possible exception
is provided by the results of a genetic screen that used trans-
poson-based insertional mutagenesis in medulloblastoma:
certain insertions promoted leptomeningeal metastasis on both
Ptch mutant and Tp53 mutant backgrounds (Wu et al., 2012).
Thus, a minority clone in a primary tumor was prompted by a
particular genetic alteration to form metastasis, providing evi-
dence that a clonal mutation can provide metastatic advantage.
In somemouse models, cancer cell dissemination is observed
before primary tumors become overtly invasive (Hu¨semann
et al., 2008; Rhim et al., 2012). Even nontransformed stem cells
placed in the circulation can infiltrate the lungs and survive for
extended periods of time (Podsypanina et al., 2008). These ob-
servations raise the possibility that early-disseminated cancer
cells may evolve independently of, and in parallel with, cancer
cells in the primary tumor (Klein, 2009). However, this model is
not independently validated by genetic data from human tumor
samples. It also remains unknown whether the progeny of the
cells that disseminate early form clinically manifest metastases
later on. It could be that cancer cells that disseminate later after
having become more aggressive in the primary tumor stand a
better chance of forming metastases.
Amplifying Oncogenic Signaling
If not through genetic alterations, how do clones with high met-
astatic propensities emerge under selective pressure? Accumu-
lating evidence from integrative analysis of metastatic xenograft
models and large clinical gene expression data sets suggests
that the selected traits augment the robustness of signaling
pathways that already are active in primary tumors, increasing
the odds that cancer cells will thrive in distant organs. In this
model, metastatic fitness is a function of the signaling amplitude
of certain oncogenic pathways.
In breast cancer cells of the triple-negative (ER–, PR–, HER2–)
subtype, several prometastatic genes have been identified that
amplify the output of cell survival and stemness pathways that
are already selected for in the primary tumor. For example,
high expression of the vascular cell adhesion molecule-1
(VCAM-1) in breast cancer cells hypersensitizes the PI3K-Akt
cell survival pathway to activation by limiting external signals.
VCAM-1 can be engaged by a4b1 integrins on tumor-associated
macrophages, leading to activation of ezrin, a PI3K and Akt
adaptor protein (Chen et al., 2011) (Figure 4A). Similarly, hyper-
activity of the tyrosine kinase Src in breast cancer cells sensitizes
the PI3K-Akt pathway to activation by CXCL12 (via its receptor
CXCR4) and IGF1 in the bone marrow stroma (Zhang et al.,
2009). Also, expression of the extracellular matrix protein tenas-
cin C (TNC) in breast cancer cells augments the output of the
Notch and Wnt pathways in support of metastasis-initiating
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Figure 4. Amplification and Expansion of Oncogenic Pathways as
Metastatic Traits
(A) Metastatic traits acquired by a quantitative gain in pathway output.
Amplification of the signaling capacity of cell survival and proliferation path-
ways provides survival and stemness advantages to disseminated cancer
cells. In this case, the level of metastatic fitness is proportional to the
robustness of the signaling pathway. In primary tumors with a relatively high
abundance of growth and survival signals, the signaling capacity of oncogenic
pathways such as PI3K, Notch, andWnt, is sufficient to support tumor growth.
However, for disseminated cancer cells reaching distant tissue microenvi-
ronment where pathway-activating signals are scarce, the signaling capacity
of these pathways is not sufficient for survival. The traits selected under such
pressure include the expression of components that amplify the signaling
capacity of the pathway in response to limiting levels of pathway activators in
the host microenvironment. In triple-negative breast cancer examples include
VCAM-1 and SRC as amplifiers of the PI3K pathway in cancer cells reaching
the lungs or the bone marrow, respectively, whereas Tenascin C and Periostin
act as amplifiers of theWNT andNOTCHpathways in cancer cells reaching the
lungs.
(B) Metastatic traits acquired by a qualitative expansion of pathway output.
Tumor-initiating pathways may additionally provide prometastatic traits by
gaining access to subsets of target genes that enhance the homing of
disseminated cancer cells to sites of survival. In this case, the level of meta-
static fitness is not linearly proportional to the signaling strength of the pathway
but depends of the pathway activating an additional set of effectors. One
example is provided by the expansion of target genes that the HIF pathway
activates in renal cell carcinoma as a result of epigenetic modifications that
open the gene promoters to access by activated HIF.
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action partner of TNC in the extracellular matrix of adult stem
cells, periostin (POSTN), binds and concentrates Wnt to the
same end (Malanchi et al., 2012) (Figure 4A).
An interpretation of these observations is that metastatic cells
need to optimize the output of their vital intracellular stemness
and survival pathways when venturing away from the primary
tumor and infiltrating alone distant sites. The activity level of
these pathways provided by the early oncogenic events may
have allowed the tumor to progress locally, but in metastatic
sites with limiting levels of trophic cues signal amplification by
factors such as VCAM-1, Src, TNC, and POSTN might be
required for cell survival. This same purpose may be served,
on a lesion-specific basis, by the noted amplifications of
KRASG12V, MYC, and CCNE1 in pancreatic cancer metastasis
(Campbell et al., 2010), or the expression of certain mediatorsof cancer invasion in melanoma (Scott et al., 2011). Conversely,
some of the genes associated with lung metastasis in breast
cancer patients and in experimental systems were found to
also be associated with primary tumor growth (Minn et al.,
2007; Minn et al., 2005). Thus, the signal optimization that is ul-
timately required for metastasis can increase the fitness of can-
cer cells and get selected for already in primary tumors.
Expanding the Output of Oncogenic Pathways
The involvement of oncogenic pathways in conferring metastatic
traits is not limited to quantitative gains in the robustness with
which these pathways transmit stemness and survival signals.
The target gene spectrum of a transcriptional program can
also undergo qualitative modulation through alterations in chro-
matin accessibility of its target loci (John et al., 2011). In the
context of metastatic progression, such modulation could
expand the output of an already activated oncogenic pathway
by allowing it to express, in addition to the basic tumorigenic
functions, metastatic phenotypes as well (Figure 4B).
One example has been identified in renal cell carcinoma, a
tumor type that is initiated by loss of the von Hippel-Lindau
tumor suppressor (VHL) and consequent activation of hypoxia-
inducible transcription factors (HIFs) (Kaelin, 2008). During
tumor progression, histone H3 lysine 27 (H3K27) demethylation
and DNA demethylation can allow the VHL-HIF pathway to
access new target genes, such as the chemokine receptor
CXCR4 and cytohesin 1-interacting protein (CYTIP), which
mediate metastatic invasion and outgrowth in the lungs and
bones (Vanharanta et al., 2013). Alterations in the distribution
of the repressive H3K27me3 chromatin mark are also associ-
ated with metastatic progression in breast cancer, where high
expression of the noncoding RNA HOTAIR can redistribute
H3K27me3 across the genome in order to repress metastasis
suppressor genes (Gupta et al., 2010). Moreover, the genome-
wide binding patterns of the estrogen receptor evolve during
breast cancer progression, with possible functional conse-
quences (Ross-Innes et al., 2012).
These examples illustrate how the genetic activation of an
oncogenic pathway during tumor initiation does not automati-
cally lead to the manifestation of this pathway’s full malignant
potential. Rather, a pathway that initially drives primary tumor
formation may evolve through quantitative and/or qualitative
amplification of its output, ultimately providing the cell with a
metastatic advantage.
Sources of Influence: Germline, Plasticity, Stroma, and
Therapy
The intrinsic metastatic traits of cancer cells may be further en-
riched or diminished by various sources of influence. Germline
variants play a role in cancer predisposition (Pharoah et al.,
2004). It is therefore also likely that human germline variants
affecting tumor progression exist, as has been demonstrated
by genetic mapping analysis in mice (Park et al., 2005). There
is evidence for a heritable component in human cancer prog-
nosis (Hemminki et al., 2011), but identifying specific poor prog-
nosis variants has proven difficult. Certain gene polymorphisms
seem to correlate with poor clinical outcome, one example being
the FGFR4G388R variant (Spinola et al., 2005). However, the diffi-
culty of conducting genome-wide association studies on cancerCancer Cell 24, October 14, 2013 ª2013 Elsevier Inc. 415
Cancer Cell
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ment of the germline component of metastatic propensity.
The ability to adopt phenotypic changes, including changes
into a more stem-like phenotype, can help cancer cells through
metastasis progression bottlenecks. Cytokine signals induce
the reactivation of developmental epithelial-to-mesenchymal
transition (EMT) programs in cancer cells (Yang and Weinberg,
2008). EMT has been proposed to provide cancer cells with
several prometastatic traits, including stemness, motility, and
resistance to therapy, all at once (Mani et al., 2008; Yang et al.,
2004). Although the role of EMT in developmental processes is
well established (Thiery et al., 2009), its significance for cancer
progression is still being defined. For example, EMT-inducing
transcriptional regulators can both promote (Yang et al., 2004)
and inhibit metastatic colonization (Ocan˜a et al., 2012; Tsai
et al., 2012). Also, metastatic lesions in patients show epithelial,
not mesenchymal features. It has been suggested that EMT pro-
vides a transient benefit in cancer cell dissemination but must be
reverted by mesenchymal-to-epithelial transition (MET) at the
metastatic site (Korpal et al., 2011; Ocan˜a et al., 2012). Although
several molecular players in EMT andMET can impart metastatic
traits in experimental systems, more work is required for an un-
derstanding of the specific changes that these mediators trigger
as well as their specific contributions to metastasis.
In all tumors, a variety of non-neoplastic stromal cells interact
with the cancer cells. This can result in both pro- and antitumori-
genic effects through often complex molecular mechanisms
(Hanahan and Coussens, 2012). Several specific examples
ranging from systemic to juxtacrine signaling loops that modu-
late primary tumor progression and metastasis have been
described, most of which represent reactive interactions be-
tween stroma and cancer cells (Acharyya et al., 2012; Calon
et al., 2012; Chen et al., 2011; DeNardo et al., 2009;
Gocheva et al., 2010; Granot et al., 2011; Karnoub et al., 2007;
Labelle et al., 2011; Lin et al., 2001; Lu et al., 2011; Magnon
et al., 2013; McAllister et al., 2008; Nieman et al., 2011; Pen-
cheva et al., 2012; Png et al., 2012; Qian et al., 2011; Schwitalla
et al., 2013; Sethi et al., 2011). Such tumor-shaping cues are not
exclusively produced by stromal cells, but other environmental
conditions, such as hypoxia, can also induce metastasis-pro-
moting changes in cancers (Chaturvedi et al., 2013; Eisinger-Ma-
thason et al., 2013; Erler et al., 2006; Gilkes et al., 2013). Tumor
stromal signals also play a role in attracting circulating metasta-
tic cells in a tumor self-seeding process that favors the clonal
expansion of these cells (Comen et al., 2011; Kim et al., 2009).
In addition to the reactive and often reversible interactions with
the components of the microenvironment, the stroma contrib-
utes to tumor progression through more subtle ways by altering
local selective pressures (Gillies et al., 2012). This can lead to the
selection of cells with enhanced metastatic potential. For
example, many of the stromal cells in tumors originate from the
bone marrow, potentially making the tumor stroma more
‘‘bone marrow-like’’ through secretion of soluble factors such
as CXCL12 and IGF1. Cancer clones evolving under the influ-
ence of such factors can then become enriched for qualities
that allow them to survive in and take advantage of the bone
marrow already before reaching the bone. This phenomenon of
‘‘metastasis seed preselection’’ provides one possible explana-
tion for the emergence of metastatic traits already at the primary416 Cancer Cell 24, October 14, 2013 ª2013 Elsevier Inc.tumor site (Zhang et al., 2013) and it could be further amplified by
tumor seeding with CTCs released from metastatic lesions (Kim
et al., 2009).
Metastatic cancers are also exposed to, and evolve under,
therapy-induced pressures (Diaz et al., 2012). Increasing evi-
dence suggests that there are molecular links between metasta-
tic cancer progression and drug resistance. For example in
breast cancer, the transmembrane protein metadherin (MTDH)
provides cancer cells with protection against chemotherapy as
well as enhanced capability to metastasize to the lung (Hu
et al., 2009). Moreover, chemotherapy can modify the tumor
microenvironment and consequently enhance the expression
of factors such as the chemokine CXCL1 that can foster therapy
resistance and promote metastasis via stromal interactions
(Acharyya et al., 2012). The traits conferring resistance to thera-
pies may therefore also drive metastatic tumor progression.
Deterministic versus Stochastic Emergence of
Metastasis Clones
Even the most predictive markers of metastatic tumor progres-
sion only indicate a higher probability of metastasis at the organ-
ismal level. At the cellular level, the degree of randomness is
even greater, as the tissues of patients who ultimately develop
one lethal metastatic lesion may carry thousands of dissemi-
nated micrometastatic cells that never took off. Therefore,
despite the identification of molecular mediators that confer a
metastatic phenotype and constitute the deterministic compo-
nent of the metastatic process, metastases also display strong
stochastic features (Talmadge and Fidler, 1982). Both syngeneic
mouse models as well as human xenograft systems have
demonstrated that at least in experimental systems stable met-
astatic cancer cell clones do exist (Talmadge and Fidler, 2010),
and analysis of clinical cancer data sets have shown that tumors
that are prone to metastasis share gene expression traits with
such clones (Bos et al., 2009; Minn et al., 2005; Nguyen et al.,
2009b; Pencheva et al., 2012; Vanharanta et al., 2013). Also,
certain well-characterized prometastatic functions are specif-
ically required for colonization of particular organ sites, such as
the bone marrow (Ell and Kang, 2012). All this suggests that spe-
cific heritablemolecular alterations, both genetic and epigenetic,
determine the capacity of cancer cells to form metastasis.
However, a stochastic nature of metastatic cancer progres-
sion is evident at several levels. First, tumor evolution feeds
from random heritable alterations that increase diversity upon
which selection can act. Of the possible evolutionary paths avail-
able for a given cancer cell clone, only some can result in a met-
astatic phenotype. As determined by the combined effects of
their tissue of origin and acquired alterations, many cancer
clones may end up in fitness peaks that are not compatible
with metastases. A phenotype that is beneficial during early
phases of tumorigenesis may thus prevent the same clone
from becoming metastatic later on (Figure 5A). Second, any can-
cer phenotype can be reached through multiple evolutionary
routes, which is reflected by the diverse mutational comple-
ments of individual cancers. As a consequence, no two cancer
clones are identical (Figure 5B). Third, as demonstrated in exper-
imental transplantation models, even within clones endowed
with high metastatic fitness, few cells actually form ametastasis.
The fate of phenotypically identical metastatic cells will therefore
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Figure 5. Levels of Stochasticity in Metastatic Cancer Progression
The stochastic nature of the evolution of metastatic cancer clones is manifest
at several levels of cancer progression.
(A) For every cancer clone, depending on their cell of origin and previous
somatic alterations, only a defined set of fitness peaks are achievable, and only
some of these peaks can reach high metastatic fitness (red peaks). Starting
from a normal cell, cancer cell clones move within fitness landscapes by
acquiring random sets of driver alterations. This leads each clone to one of the
possible fitness peaks (red arrows). The ratio of possible metastatic and
nonmetastatic evolutionary paths for a given cancer clone may vary greatly
depending on the cell of origin or initial mutational events. Some tumors may
have none whereas some may have several ways to become metastatic. This
is reflected in the fact that the incidence of metastatic progression varies
between tissue and tumor types.
(B) The (epi)genetic changes that allow different cancer clones to climb up the
same metastatic fitness peak are never identical. Thus, even tumors that arise
from identical normal cells through identical tumor-initiating mutations, and
that ultimately display clinically similar metastatic phenotypes, have acquired
those metastatic traits through a different evolutionary path (dotted red lines).
(C) Of the cellular progeny of a cancer clone that, in principle, have the qualities
that are required for metastatic colonization, only a minuscule fraction (a) will
ever form meaningful metastasis. Thus, even for cells that have reached a
metastatic fitness peak, the attrition rates remain extremely high. This means
that the fate of phenotypically identical metastatic cells is in most cases not
identical.
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would be compatible with a stochastic model whereby highly
aggressive cancer cell clones that emerge from primary onco-
genic events all have the potential to form metastasis at a very
low frequency (Jones et al., 2008).
Closing the circle, some of the observed randomness in the
metastatic process might in fact be the consequence of factors
yet to be discovered. For example, the formation of metastasis
may be possible only at certain defined microenvironmental
niches, such as in the hematopoietic stem cell niche in the
bone marrow (Ding et al., 2012a; Shiozawa et al., 2011). The
need of cancer cells to fall in a suitable niche in order to thrive
could provide a partial explanation to the stochastic nature of
metastasis-formation (Ghajar et al., 2013). At a more general
level, systemic inflammatory reactions triggered by primary
tumors may modulate the stroma at distant organs to unevenly
increase metastatic colonization of otherwise resistant tissues
(Kaplan et al., 2005).
The development of metastatic cancer clones is thus the end
result of an intimate interplay between selection and stochasticevents. As we learn more, an increasing fraction of the random-
ness in the process may turn out to be nonrandom. However,
only by appreciating that metastasis results from a combination
of nonrandom determinants and random chance we may arrive
at a comprehensive understanding of the origins of metastatic
traits.
Conclusions and Perspective
Progression from an early neoplastic lesion to a metastatic can-
cer is a long evolutionary process that often takes years, if not
decades. Rather than involving mutations that individually pro-
vide strong competence to perform multiple metastasis steps,
metastasis involves multiple alterations, each providing a slight
selective advantage in at least one of the many steps of metas-
tasis. Multiple such alterations must accumulate for a metastatic
clone to emerge. The metastatic cell is a rare end result of exten-
sive genomic and epigenomic tinkering. Identifying the most
demanding steps in metastasis and therapeutically targeting
the metastatic traits that mediate these steps are aims of future
research.
Even with the most aggressive metastatic clones, the success
rate of metastatic colonization remains low. The vast majority of
disseminated cancer cells in any target tissue die before they can
form metastatic colonies. The molecular mechanisms of this
widespread death are for the most part unknown. Identifying
what kills disseminated cancer cells en mass may provide clues
for therapeutic intervention against the survivors.
Metastatic cancer cell clones are genetically distinct and do
not necessarily represent the majority of a primary tumor. Clonal
heterogeneity within primary tumors is a source for the selection
of metastatic cancer cells. Sampling of multiple locations within
a tumors and its metastasis is needed in order to establish the
clonal evolution of metastatic processes.
High-throughput genetic analysis of primary human cancers
and their metastatic counterparts have identified metastasis-
associated mutations but not metastasis-specific mutations.
Many, though not all, likely are passenger events without causal
role in metastasis progression. Hence, from a genetic perspec-
tive, metastasis is an extension of primary tumor progression,
not a distinct step with characteristic mutational determinants.
The lack of singular mutational events that would selectively
confer metastatic potential may reflect the fact that the pheno-
types of metastatic cells are complex and not achievable
through a single alteration.
Cancers evolve under strong microenvironmental and ther-
apy-induced pressures. Both stromal cells and therapeutic
agents can limit cancer growth but they can also skew the clonal
distribution of a tumor and thus provide opportunities for the
expansion andmetastatic dissemination of selected cancer sub-
clones. Therapy-resistance and metastasis are thereby molecu-
larly linked.
Mutational activation of oncogenic pathways does not auto-
matically lead to the manifestation of their full tumorigenic and
metastatic potential. In metastatic cancer cells, signaling path-
ways have been tuned through selective pressures to become
as prometastatic as possible, resorting to many of the principles
enunciated above. Unlike developmental processes with layers
of regulators providing robustness to the system, the emergence
of highly metastatic cancer clones often seems to beCancer Cell 24, October 14, 2013 ª2013 Elsevier Inc. 417
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Reviewaccompanied by the loss of such safety nets in order to achieve
maximal output of oncogenic pathways. This may lead to vulner-
abilities that could be useful for therapeutic intervention.
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